drugset / Trial / NCT02034097
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Foretinib (GSK1363089) is an investigational, oral, multikinase inhibitor involved in invasion, migration, and angiogenesis. This is a phase II, open label, uncontrolled, parallel, multi-cohort, multicenter 2-stage study to assess the safety and efficacy of foretinib and erlotinib combination therapy and foretinib monotherapy in genomic subpopulations of Non-Small-Cell Lung Cancer (NSCLC) subjects.
Timeline
- Start
- 2014-04
- Primary completion
- 2014-04
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Foretinib | Small molecule | 45 mg | Oral |
| Subject | Foretinib | Small molecule | 60 mg | Oral |